NR3C2 and heart failure: Therefore, the MINIMIZE STEMI trial7 was designed to assess the benefit of mineralocorticoid receptor antagonist (MRA) therapy in STEMI patients without heart failure on reducing MI size and preventing adverse left ventricular (LV) remodeling.